欣吉健康

最新新闻

• 评级变动
  Analysts Offer Insights on Healthcare Companies: Hinge Health, Inc. Class A (HNGE) and Precision BioSciences (DTIL)
  TipRanks · 2026/9/28
• 评级变动
  Stifel Maintains Hinge Health(HNGE.US) With Buy Rating, Raises Target Price to $90
  \u5e02\u573a\u8d44\u8baf · 2026/7/27
• BofA Securities Initiates Hinge Health(HNGE.US) With Buy Rating, Announces Target Price $110
  \u5e02\u573a\u8d44\u8baf · 2026/9/29
• 评级变动
  Citizens JMP Maintains Hinge Health(HNGE.US) With Buy Rating, Raises Target Price to $96
  \u5e02\u573a\u8d44\u8baf · 2026/7/27
• 评级变动
  Evercore ISI Reaffirms Their Buy Rating on Hinge Health, Inc. Class A (HNGE)
  TipRanks · 2026/8/4
• 评级变动
  Barclays Maintains Hinge Health(HNGE.US) With Buy Rating, Maintains Target Price $97
  \u5e02\u573a\u8d44\u8baf · 2026/8/4
• 评级变动
  Hinge Health, Inc. Class A (HNGE) Gets a Buy From Morgan Stanley
  TipRanks · 2026/8/4
• Truist Financial Initiates Hinge Health(HNGE.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/9/28
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Hinge Health, Inc. Class A (HNGE) and Agilon Health (AGL)
  TipRanks · 2026/9/28
• 评级变动
  Analysts Conflicted on These Healthcare Names: Neogen (NEOG), Pfizer (PFE) and Hinge Health, Inc. Class A (HNGE)
  TipRanks · 2026/7/30
• 评级变动
  Analysts Have Conflicting Sentiments on These Healthcare Companies: Hinge Health, Inc. Class A (HNGE) and DaVita (DVA)
  TipRanks · 2026/8/5
• Form 144 | Hinge Health(HNGE.US) 10% Stockholder Proposes to Sell 7.57 Million in Common Stocks
  \u5e02\u573a\u8d44\u8baf · 2026/10/1
• 评级变动
  Truist Financial Maintains Hinge Health(HNGE.US) With Buy Rating, Announces Target Price $112
  \u5e02\u573a\u8d44\u8baf · 2026/8/11
• 评级变动
  Morgan Stanley Maintains Hinge Health(HNGE.US) With Buy Rating, Raises Target Price to $117
  \u5e02\u573a\u8d44\u8baf · 2026/8/5
• Form 144 | Hinge Health(HNGE.US) 10% Stockholder Proposes to Sell 47.73 Million in Common Stocks
  \u5e02\u573a\u8d44\u8baf · 2026/10/1
• 评级变动
  Stifel Maintains Hinge Health(HNGE.US) With Buy Rating, Raises Target Price to $115
  \u5e02\u573a\u8d44\u8baf · 2026/9/8
• 评级变动
  Morgan Stanley Maintains Hinge Health(HNGE.US) With Buy Rating, Maintains Target Price $117
  \u5e02\u573a\u8d44\u8baf · 2026/8/25
• 评级变动
  Truist Financial Maintains Hinge Health(HNGE.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/8/5
• 评级变动
  A Quick Look at Today's Ratings for Hinge Health(HNGE.US), With a Forecast Between $96 to $110
  \u5e02\u573a\u8d44\u8baf · 2026/8/5
• Form 144 | Hinge Health(HNGE.US) 10% Stockholder Proposes to Sell 39.14 Million in Common Stocks
  \u5e02\u573a\u8d44\u8baf · 2026/10/1

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。